Retatrutide vs tirzepatide, honestly compared

What this guide covers

One is approved, available and proven over 72 weeks. The other posted a bigger number in a smaller, shorter trial and is still in Phase 3. How the triple agonist compares with Mounjaro and Zepbound, without the hype. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The short answer. Tirzepatide (Mounjaro, Zepbound) is an approved dual agonist, GIP plus GLP-1, with completed Phase 3 trials, FDA labels, and millions of prescriptions behind it. Retatrutide adds a third receptor, glucagon, and posted a larger average weight reduction in its mid-stage trial, about 24 percent at 48 weeks versus tirzepatide's roughly 21 percent at 72 weeks in its own flagship trial. Those numbers come from different trials and cannot be read as a race result. Today the comparison is simple: one of these you can be prescribed; the other you can only read about. The interesting question is what happens if retatrutide's Phase 3 confirms its Phase 2.
• Two receptors versus three. Tirzepatide pairs GLP-1's appetite-and-glucose effects with GIP, which appears to amplify weight effects and may ease nausea. Retatrutide keeps both and adds glucagon-receptor agonism, which raises energy expenditure and pushes the liver to burn fat, attacking weight from the spending side as well as the intake side. The same addition explains retatrutide's distinctive watch item, a measurable heart-rate increase, which tirzepatide does not produce to the same degree. More receptors is a hypothesis about better results, not a guarantee; the third receptor has to pay for its side effects in Phase 3.
• The numbers, with their asterisks. Retatrutide Phase 2: about 24 percent average reduction at 48 weeks, 338 participants, curve still falling at the end. Tirzepatide SURMOUNT-1: about 21 percent at 72 weeks at the top dose, 2,539 participants, Phase 3 rigor. The asterisks matter more than the decimals. Phase 2 trials select responsive populations and regularly overstate what Phase 3 confirms; the trials differ in length, size and design; and 'average' hides enormous individual spread on every drug in this class. The defensible statement: retatrutide's early data is the strongest the field has produced at that stage, and tirzepatide's data is the strongest that has actually finished.
• Side effects compared. The shared profile is the class profile: nausea, diarrhea, vomiting, constipation, worst during titration, dose-dependent on both drugs. Tirzepatide's profile is documented at Phase 3 scale and in years of real-world use, with the boxed warnings and label cautions readers can check today. Retatrutide adds the glucagon-driven heart-rate increase and the skin-sensitivity reports from Phase 2, both unresolved questions rather than settled risks. On current knowledge, tirzepatide is the better-characterized drug by an order of magnitude, which is exactly what approval means.
• The decision nobody actually faces yet. No patient chooses between these drugs today, because only one is purchasable. The real-world versions of the question: if you qualify for tirzepatide now, waiting years for a possibly-stronger drug means years of untreated obesity, which is rarely the right trade, and switching later remains possible. If tirzepatide has not worked for you, retatrutide is a concrete reason for hope and the TRIUMPH trials are recruiting on clinicaltrials.gov. And if your plan covers neither, our cost guides on the approved drugs are the practical reading. When retatrutide's Phase 3 publishes, this page gets rewritten with the real numbers, dated.

Frequently asked questions